This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have been advisors and consultants to manufacturers of both branded biologics and biosimilar products. The analysis in this study was supported by their current employers and undertaken independently of any other organizations.
Supplementary information
Supplementary information S1 (box)
Data sources, analysis methods, and additional data and analyses (PDF 1629 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Grabowski, H., Guha, R. & Salgado, M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov 13, 99–100 (2014). https://doi.org/10.1038/nrd4210
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4210
- Springer Nature Limited
This article is cited by
-
Financing Drug Innovation in the US: Current Framework and Emerging Challenges
PharmacoEconomics (2020)
-
Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
BMC Health Services Research (2019)
-
Biologics, biosilimars, and biobetters: different terms or different drugs?
Eye (2019)
-
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Advances in Therapy (2019)
-
Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review
PharmacoEconomics - Open (2019)